Topcoin - Beigene at year end 2018 with $1.8 billion of cash and short term investments, most of which came from a 2018 Hong Kong listing, would not be my first choice for a buyer of RVX. Their sales for the last quarter of 2018 were just under $200 million. In order to purchase RVX they would have to uses a lot of leverage or issue us a lot of shares or both. With 2200 employees, 800 of which are in China I would be somewhat concerned about their ability to scale up their world wide sales force to give us the exposure needed to capture the largest bite of that world market. Their focus today seems to be toward oncology which would be a total direction change for them if they acquired apabetalone. It could be done but it wouldn't be my first choice. 

Being a Zenith shareholder IMO I would lean more toward a BP that has feet on the ground in the cardio, CKD, diabetes, and or dementia markets already. Building out a new sales force world wide with new products is time consuming and expensive. As a royalty holder I would prefer a company with an in place sales force experienced in the markets mentioned above and the money to put behind the launch of a very exciting new product.

All IMO being totally selfish, dyodd.

tada